KashMOX 625
Amoxicillin & Potassium Clavulanate Tablets I.P.
KashMOX 625 is TrPharma's flagship broad-spectrum antibiotic, developed under the medical leadership of Dr. Ashwani Dhar MD DMI. Combining Amoxicillin with Clavulanic Acid for enhanced efficacy against resistant bacteria.
Composition (Per Tablet)
- Amoxicillin Trihydrate I.P. eq. to Amoxicillin - 500 mg
- Potassium Clavulanate Diluted I.P. eq. to Clavulanic Acid - 125 mg
Therapeutic Indications
KashMOX 625 is indicated for the treatment of bacterial infections caused by susceptible organisms
Respiratory Tract Infections (RTI)
Sinusitis, bronchitis, pneumonia, tonsillitis
Urinary Tract Infections (UTI)
Cystitis, pyelonephritis
Skin & Soft Tissue Infections
Cellulitis, wound infections, abscesses
Dental Infections
Dental abscess, periodontal infections
Bone & Joint Infections
Osteomyelitis, septic arthritis
Intra-abdominal Infections
Peritonitis, biliary tract infections
Why Choose KashMOX 625
Developed under the medical leadership of Dr. Ashwani Dhar for optimal therapeutic outcomes
Broad-Spectrum Coverage
Effective against gram-positive and gram-negative bacteria including beta-lactamase producing strains that resist ordinary amoxicillin
Synergistic Action
Clavulanic acid inhibits beta-lactamase enzymes, protecting amoxicillin and extending its antibacterial spectrum
Fast Absorption
Rapid oral absorption with peak plasma concentration reached within 1-2 hours for quick therapeutic action
WHO-GMP Certified
Manufactured in World Health Organization Good Manufacturing Practice certified facilities ensuring highest quality
Well Tolerated
Excellent safety profile when taken as directed. Take with food to minimize gastrointestinal effects
Doctor-Developed
Developed under the medical leadership of Dr. Ashwani Dhar MD DMI, ensuring clinical efficacy standards
Dosage & Administration
Adult Dosage
One tablet (625mg) two to three times daily, depending on severity of infection.
- Mild to moderate infections: Twice daily
- Severe infections: Three times daily
- Duration: 5-14 days as prescribed
Important Notes
- Take with or immediately after food to reduce GI effects
- Complete the full course even if symptoms improve
- Store below 25°C in a dry place
- Consult physician before use if pregnant or nursing
Dr. Ashwani Dhar
MD, DMI
Developed Under Medical Leadership
KashMOX 625 was developed under the medical leadership of Dr. Ashwani Dhar MD DMI, Founder & CEO of TrPharma. Drawing from his extensive clinical experience and understanding of antibiotic resistance patterns, Dr. Dhar ensured KashMOX 625 meets the highest standards of therapeutic efficacy.
As a physician who has treated thousands of patients, Dr. Dhar understands the importance of effective, affordable antibiotics. KashMOX 625 represents his commitment to making quality healthcare accessible to all.
Get KashMOX 625 Today
WHO-GMP certified quality. Doctor-developed. Affordable pricing. Order now from TrPharma.